Miscellaneous

     

pathologytreatmentpatient Demonstrated benefit and harm k      
melanomaInterferon alphanot classified

versus placebo or control

No demonstrated result for efficacy

rIFN alpha-2b inferior to observation in terms of OS in EORTC18871/DKG 80-1 stage III

1 trialmeta-analysis
melanomaInterferon alphaadjuvant

versus placebo or control

No demonstrated result for efficacy

1 trialmeta-analysis
melanomaipilimumabadjuvant

versus placebo or control

ipilimumab superior to placebo in terms of recurrence free survival in EORTC 18071 (Eggermont), 2015 (adjuvant patients)

ipilimumab inferior to placebo in terms of grade 3-4 in EORTC 18071 (Eggermont), 2015 (adjuvant patients)

1 trialmeta-analysis
melanomanivolumabnot classified

versus placebo or control

No demonstrated result for efficacy

1 trialmeta-analysis
melanomapembrolizumabadjuvant

versus placebo or control

pembrolizumab superior to placebo in terms of recurrence free survival in KEYNOTE-054, 2018 (adjuvant patients)

pembrolizumab inferior to placebo in terms of Grade 3 or 4 drug-related adverse events in KEYNOTE-054, 2018 (adjuvant patients)

pembrolizumab inferior to placebo in terms of Vitiligo any grade in KEYNOTE-054, 2018 (adjuvant patients)

1 trialmeta-analysis
melanomatrametinib + dabrafenib adjuvant

versus placebo or control

No demonstrated result for efficacy

1 trialmeta-analysis
melanomavemurafenibnot classified

versus placebo or control

No demonstrated result for efficacy

1 trialmeta-analysis
sarcomapazopanibnot classified

versus

No demonstrated result for efficacy

1 trialmeta-analysis